640 Results

Phase III trial of Instiladrin meets primary endpoint in unresponsive non-muscle invasive bladder cancer.- FerGene

 Added 14 hours ago

FerGene announced positive results from the pivotal Phase III clinical trial evaluating Instiladrin (nadofaragene firadenovec) (rAd-IFN/Syn3), an investigational gene therapy,...

AURORA phase III trial of Luveniq meets primary endpoint in lupus nephritis.- Aurinia Pharma

 Added 1 day ago

Aurinia Pharmaceuticals Inc. announced positive top-line results announced positive efficacy and safety results from its pivotal AURORA Phase III trial...

Seattle Genetics + Astellas collaborate with Merck Inc., to evaluate enfortumab vedotin in combination with Keytruda to treat metastatic urothelial cancer.

 Added 4 days ago

Seattle Genetics, Inc.and Astellas Pharma Inc. announced a clinical collaboration agreement with Merck, known as MSD outside the United States...

Ferring launches new company, FerGene, to focus on development of nadofaragene firadenovec to treat non-muscle invasive bladder cancer.

 Added 11 days ago

Ferring Pharmaceuticals and Blackstone Life Sciences announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an...

Myovant Sciences announces 97% response rate in positive phase III HERO study of once-daily, oral relugolix in men with advanced prostate cancer.

 Added 17 days ago

Myovant Sciences announced that the Phase III HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint...

FDA approves Fetroja for complicated urinary tract infections.- Shionogi

 Added 21 days ago

The FDA has approved Fetroja (cefiderocol), from Shionogi, an antibacterial drug for treatment of patients 18 years of age or...

Phase III CONFIRM study of Variquel meets primary endpoint in hepatorenal syndrome type 1.- Mallinckrodt

 Added 24 days ago

Mallinckrodt announced results from its pivotal Phase III CONFIRM study to assess the efficacy and safety of its investigational agent...

Announcing a new symposium on prostate cancer being held at the 11th European Multidisciplinary Congress on Urological Cancers

 Added 25 days ago

Epgonline.org is excited to announce an upcoming symposium to be held at EMUC19, the 11th European Multidisciplinary Congress on Urological Cancers.

Anifrolumab demonstrated superiority across multiple efficacy endpoints in patients with systemic lupus erythematosus in phase III TULIP 2 trial. - AstraZeneca

 Added 25 days ago

AstraZeneca will tomorrow present detailed results from the positive Phase III TULIP 2 trial for anifrolumab, a potential new medicine...

Phase III CREDENCE study of Invokana finds benefits for kidney function in diabetic nephropathy.- Janssen Pharma

 Added 26 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of an important new analysis from the landmark Phase III...

Load more